SWP
TVTX icon

Strategic Wealth Partners’s Travere Therapeutics TVTX Stock Holding History

Strategic Wealth Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.62K Hold
290
– – ﹤0.01% 922
2025
Q4 		$11.1K Hold
290
– – ﹤0.01% 861
2025
Q3 		$6.93K Hold
290
– – ﹤0.01% 979
2025
Q2 		$4.29K Buy
+290
New +$4.81K ﹤0.01% 919

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Strategic Wealth Partners's TVTX Position: Q1 2026 in Review

Strategic Wealth Partners held its Travere Therapeutics (TVTX) position steady in Q1 2026 at 290 shares worth $8.62K. The position accounts for ﹤0.01% of the portfolio, ranked #922.

Strategic Wealth Partners first reported a position in TVTX in Q2 2025 and has held it in 4 quarters since. The position peaked at $11.1K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Strategic Wealth Partners held 290 shares of Travere Therapeutics worth $8.62K as of Q1 2026.
  • Strategic Wealth Partners left its Travere Therapeutics share count unchanged in Q1 2026.
  • Travere Therapeutics made up ﹤0.01% of Strategic Wealth Partners's portfolio in Q1 2026, its #922 holding.
  • Strategic Wealth Partners first reported a position in Travere Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Strategic Wealth Partners's Travere Therapeutics position peaked at $11.1K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Strategic Wealth Partners's 13F filing for Q1 2026, filed 12 May 2026.